Logo

Genethon to Use Hybrigenics Y2H Platform, Software for Muscular Dystrophy Research

Dec 21, 2005

NEW YORK, Dec. 21 (GenomeWeb News) - Genethon, a research center funded by the French Muscular Dystrophy Association, will use Hybrigenics' yeast two-hybrid screening platform to study muscle cell proteins, Hybrigenics said today.

 

Genethon conducted a pilot screening study with Hybrigenics in 2004 and 2005 that identified several proteins involved in muscular dystrophies, the company said. Genethon will now use the screening platform along with Hybrigenics' protein interaction mapping software, PIMRider, to discover interactions between the proteins.

 

Hybrigenics said that Genethon will use the technology to map "genome-wide interactomes" to study protein mechanisms. Under the agreement, all data will belong to Genethon.

 

France's Muscular Dystrophy Association provided €894,000, or $1.2 million, in funding to support the project.

Breaking News
The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.